| Sanofi-Aventis (Suisse) SA - Mycostatin, suspension buvable/buccale | | 33043 | | 01 | | Mycostatin | | suspension buvable/buccale | | A07AA02 | | Nystatin | | 18.05.1967 | | |
| | Composition | | nystatinum 100000 U.I., saccharum 500 mg, glycerolum, saccharinum natricum, carmellosum natricum, dinatrii phosphas dihydricus, E 218 1 mg, propylis parahydroxybenzoas 0.2 mg, ethanolum 8.16 mg, aromatica (cerise) cum alcohol benzylicus, menthae piperitae aetheroleum, cinnamaldehydum, natrii hydroxidum, acidum hydrochloridum, aqua purificata ad suspensionem pro 1 ml corresp. natrium max. 0.78 mg. | | Packungsbestandteile | | suspension buvable/buccale | | | | | | | | Principe actif | Concentr. |
|---|
| Nystatine | 100000 UI/ml |
| | BAG: Principe actif | Concentr. |
|---|
| Nystatine | 100000 UI |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| Acidum Hydrochloridum | | | | Aromatica (Cerise) cum Alcohol Benzylicus | | | | Carmellose Sodique | | | | Cinnamaldehydum | | | | Disodium Phosphate Dihydrate | | | | E 218 | 1 mg/ml | conserv. | | Ethanol | 8.16 mg/ml | | | Glycerol | | | | Menthae Piperitae Aetheroleum | | | | Sodium Hydroxide | | | | Propylis Parahydroxybenzoas | 0.2 mg/ml | | | Saccharinum Natricum | | | | Saccharum | 500 mg/ml | |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 015 | 24 ml | 2.92 | 12.35 | B | LS | Oui |
|
|
